Skip to Content

Pathfinder Cell Therapy Inc PFND

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (“PCs”) themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.

Contact
12 Bow Street
Cambridge, MA, 02138
T +1 617 245-0289
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2015
Fiscal Year End Dec 31, 2015
Stock Type Distressed
Employees 1